Karyopharm Therapeutics Received FDA Approval for Labeling for XPOVIO
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208088
What 5 Analyst Ratings Have To Say About Karyopharm Therapeutics
Over the past 3 months, 5 analysts have published their opinion on Karyopharm Therapeutics (NASDAQ:KPTI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Karyopharm Announces Upcoming Presentations Of Phase 3 SIENDO Study Of Selinexor In Patients With Advanced Or Recurrent Endometrial Cancer Mar. 17 And 19
Study Results to be Presented at the European Society of Medical Oncology's Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on Women's Cancer
Company to Host
RBC Capital Maintains Sector Perform on Karyopharm Therapeutics, Lowers Price Target to $8
RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Sector Perform and lowers the price target from $12 to $8.
68 Biggest Movers From Yesterday
Gainers
ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.
Mid-Afternoon Market Update: Dow Gains 2%; SAB Biotherapeutics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 2% on Wednesday.
41 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday.
Mid-Day Market Update: Nasdaq Surges 150 Points; US Crude Oil Inventories Fall By 2.6M Barrels
U.S. stocks extended gains midway through trading, with the Nasdaq index jumping 150 points on Wednesday.